A NLC system was developed for the oral co-delivery of raloxifene, a synthetic selective estrogen receptor modulator, and naringin, a flavonoid phytochemical with known anticancer activity, targeting estrogen receptor–positive breast cancer [235]. The gene discussed is ESR1; the disease is breast cancer.